ERNEXA THERAPEUTICS INC. - COMMON STOCK

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

22 Apr 2025 07:29:59 By Nasdaq GlobeNewswire

Ernexa Therapeutics Closes New Funding Round

03 Apr 2025 07:55:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease

25 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

26 Feb 2025 07:30:56 By Nasdaq GlobeNewswire

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

28 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

14 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

09 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

03 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

25 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

14 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

30 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

17 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

10 May 2024 07:00:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

08 May 2024 08:31:43 By Nasdaq GlobeNewswire

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

20 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

03 Jan 2024 15:15:00 By Nasdaq GlobeNewswire

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

20 Dec 2023 15:15:31 By Nasdaq GlobeNewswire

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

14 Dec 2023 17:56:25 By Nasdaq GlobeNewswire